Project Details
Description
An investigator initiated clinical trial of combined immunotherapy (PD1-inhibitor) and irreversible electroporation in patients with metastatic pancreatic cancer.
The aim is to examine the efficacy and safety of the combined treatment.
The aim is to examine the efficacy and safety of the combined treatment.
| Short title | Electroporation Potentiated Immunotherapy in Cancer – 1.st study |
|---|---|
| Acronym | EPIC-1 |
| Status | Curtailed |
| Effective start/end date | 01/01/2021 → 09/04/2024 |
Collaborative partners
- Odense University Hospital
Keywords
- pembrolizumab
- irreversible electroporation
- efficacy
- safety
- cancer
- pancreatic cancer
- pancreas
- immunotherapy
- ablation
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
Research output
- 1 Journal article
-
Pembrolizumab followed by irreversible electroporation of a liver metastasis in pancreatic cancer patients
Flak, R. V., Kofod-Olsen, E., Sølvsten, N. D., Naujokaite, G., Agger, R., Stender, M. T., Christensen, S., Shim, S., Poulsen, L. Ø., Detlefsen, S., Thorlasius-Ussing, O. & Ladekarl, M., 18 Oct 2024, In: iScience. 27, 10, 19 p., 111026.Research output: Contribution to journal › Journal article › Research › peer-review
Open AccessFile51 Downloads (Pure)
Press/Media
-
Forskere vil afprøve immunterapi og elektriske impulser mod bugspytkirtelkræft
06/07/2020
1 item of Media coverage
Press/Media: Press / Media